The study compared 183 patients with rheumatoid arthritis treated with omega-3 PUFAS per day and 187 patients treated with a placebo as controls that were enrolled in ten randomized controlled trials.
At the study’s conclusion, the researchers noted that in addition to reducing the use of NSAID, using Omega-3 PUFAS improved several subjective measures of joint pain including tender point count, swollen joint count, morning stiffness and physical function.
The researchers concluded, "…that the use of omega-3 PUFAs for >3 months reduces NSAID consumption by RA patients."
Omega XL is one of only two Omega-3 supplements sold in the world that contains the patented stabilized marine lipid extract PCSO-524™ derived only from the New Zealand green-lipped mussel, with 30 healthy fatty acids including DHA and EPA. Sold in other parts of the world under its sister brand name Lyprinol, Omega XL is manufactured exclusively by Great HealthWorks Inc., and is the most widely available omega-3 fish oil supplement containing the potent PCSO-524™ marine lipid extract. To find more information about Omega XL and PCSO-524™ visit http://www.OmegaXL.com
Source: Archives of Medical Research, 2012 Jul 23.
Omega-3 Polyunsaturated Fatty Acids and Rheumatoid Arthritis Treatment: A Meta-analysis.
Lee YH, Bae SC, Song GG.
Department of Internal Medicine, Division of Rheumatology, Korea University College of Medicine, Seoul, Korea.
http://www.ncbi.nlm.nih.gov/pubmed/22835600
Source:
prweb.com
